Asset sale Announced Sponsor buyer
Veristat acquisition of Certara Regulatory and Medical Writing business
US$135m consideration
Announced 22 Apr 2026
Advisers
Certara Regulatory and Medical Writing business
Target
- Financial adviser
- Legal adviser
- Target
- Certara Regulatory and Medical Writing business
- Acquirer
- Veristat
- Sponsor
- Windrose Health Investors
- Seller
- Certara
- Target based in
- United States
- Buyer based in
- United States
- Seller based in
- United States
- Sector
- Pharma Services
- Tags
- Pharma Services, Life Sciences
In the league tables
Similar deals
- Webster Equity Partners acquisition of Lifecore Biomedical Sep 2026 · US$664m · Pharma Services
- Azenta UK acquisition of UK Biocentre Mar 2026 · US$26.9m · Life Sciences
- McKesson acquisition of Precision Medicine Group Aug 2026 · US$2.3bn · Clinical Trial Services
- Everest Clinical Research acquisition of Firma Data Services Sep 2026 · Clinical Trial Services
- Kincell Bio and Cellipont Bioservices merger Sep 2026 · Pharma Services
Sources
- Apr 2026 Guggenheim Securities: Financial Advisor to Veristat, a Portfolio Company of Windrose Health Investors, on its Acquisition of the Regulatory and Medical Writing Business of Certara guggenheimsecurities.com
- Apr 2026 Perella Weinberg Partners: Exclusive financial advisor to Certara on the sale of its regulatory and medical writing business to Veristat Undisclosed pwpartners.com
- 22 Apr 2026 Press release (EX-99.1, exhibit), Certara Enters Definitive Agreement for the sec.gov
